|
|
|
Volumn 11, Issue 1, 2002, Pages 45-46
|
|
A health care management company's experience with palivizumab.
a
a
USA
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
MONOCLONAL ANTIBODY;
PALIVIZUMAB;
ARTICLE;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
COST CONTROL;
ECONOMICS;
HEALTH CARE PLANNING;
HEALTH MAINTENANCE ORGANIZATION;
HUMAN;
MEDICAID;
NEWBORN;
PUBLICATION;
RISK FACTOR;
STANDARD;
UNITED STATES;
VIRUS INFECTION;
ANTIBODIES, MONOCLONAL;
ANTIVIRAL AGENTS;
CLINICAL TRIALS;
COST SAVINGS;
COST-BENEFIT ANALYSIS;
FORMULARIES;
HEALTH MAINTENANCE ORGANIZATIONS;
HUMANS;
INFANT, NEWBORN;
MEDICAID;
NEW JERSEY;
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;
RISK FACTORS;
STATE HEALTH PLANS;
UNITED STATES;
|
|
EID: 0036365785
PISSN: 10623388
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
